



Engineered bacteriophage lysins as novel anti-infectives

Hang Yang, Junping Yu and Hongping Wei*

Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China

Edited by:

Marta Martins, University College Dublin, Ireland

Reviewed by:

Melinda J. Mayer, Institute of Food Research, UK

Taoufik Ghrairi, Faculty of Medicine Ibn El Jazzar of Sousse, Tunisia

Pedro Fernandes, Instituto Superior Tecnico - Universidade de Lisboa, Portugal

*Correspondence:

Hongping Wei, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
e-mail: hpwei@wh.iov.cn

Bacteriophage lysins, the highly evolved specific peptidoglycan hydrolases, have long been demonstrated to be effective enzybiotics in various infectious models. The modular structure of lysins makes it possible to design bioengineered lysins that have desired properties, such as higher activity, or broader killing spectrum. Moreover, lysins can even be engineered to kill Gram-negative bacterial pathogens from without, a property that is not present in natural lysins. In this era of ever increasing multidrug resistant pathogens, engineered lysins represent a new class of enzybiotics that are powerful and readily available to fight antimicrobial resistance.

Keywords: lysin, chimeolysin, artilysin, bacteriophage, lysin engineering, enzybiotics

INTRODUCTION

Bacteriophage lysins are novel murein hydrolases encoded by dsDNA phages in the late phase of infection cycle for the release of progeny virions (Loessner, 2005). These enzymes are usually genus-specific and highly active against bacterial peptidoglycan and capable of digesting the cell walls of susceptible bacteria, including multidrug resistant Gram-positive pathogens (Fischetti, 2006). Therefore, lysins have been considered as promising anti-infective enzybiotics with potential important applications in medicine and biotechnology in the current age of mounting antimicrobial resistance (Fischetti et al., 2006).

Currently, there are excellent reviews that have dealt with the characteristics of lysins and their applications, both as alternative enzybiotics in medical-oriented *in vitro* and *in vivo* tests (Fischetti, 2005; Fenton et al., 2010b; Knoll and Mylonakis, 2014), and as preservatives in the food industry (Callewaert et al., 2011; Oliveira et al., 2012). In the experimental models of sepsis (Schuch et al., 2002; Gilmer et al., 2013), pneumonia (Loeffler et al., 2001; Witzentrath et al., 2009), endocarditis (Entenza et al., 2005), meningitis (Grandgirard et al., 2008), nasopharyngeal infection (Kiser et al., 1999), canine pyoderma (Junjappa et al., 2013), endophthalmitis (Singh et al., 2014), skin and vaginal decolonization (Cheng et al., 2005), lysins have been used as effective anti-infectives to eliminate pathogens systemically and topically from mucosal surfaces and biofilms, including methicillin- and vancomycin-resistant *Staphylococcus aureus*, vancomycin-resistant *Enterococcus faecalis* and *E. faecium*, and penicillin-resistant *Streptococcus pneumoniae*. According to the opinion of Vincent A. Fischetti, several unique characteristics of lysins makes them attractive enzybiotics over small molecule antibiotics (Fischetti, 2008, 2010). These include (i) their specificity for the pathogens without disturbing the normal microflora, (ii) the low chance of developing bacterial resistance, and (iii)

their ability to kill colonizing pathogens on mucosal surfaces. One possible problem of lysins may be their immunogenicity as protein molecules. However, studies thus far have illustrated that lysin-specific antibodies are non-neutralizing both *in vitro* and *in vivo* (Rashel et al., 2007; Daniel et al., 2010; Yang et al., 2014), which means that lysins can be used repeatedly in the treatment of infections caused by susceptible pathogens. Clinical trials are being conducted or prepared to assess the safety and pharmacokinetic properties of lysins in humans (Pastagia et al., 2013). For instance, a lysin against staphylococci P128 (George et al., 2012), has already stepped into phase II clinical trial (<http://www.clinicaltrials.gov/ct2/show/NCT01746654?term=gangagen&rank=1>) for studying its effectiveness in reducing the nasal carriage of *S. aureus* in humans. Although there are no lysins being used as medicine yet, it is believed that the breakthrough might come first for treating mucosal infections, such as nasal decolonization and wound healing. Furthermore, the combination of lysins with current antibiotics would be very effective to treat infections caused by multidrug resistant bacteria (Schuch et al., 2014).

Apart from natural lysins, there is an ever-growing interest in the engineered lysins created through modification or rational design from natural lysins. A perfect lysin that is ideal for anti-infective applications should maintain high bioavailability and activity. However, the genus-specific natural lysins are limited when treating infections caused by mixed bacteria from multiple genera. For example, a lysin with a relatively broad lytic spectrum that could lyse more than one genus of pathogens is preferred when treating mucous associated infections (human mucous membranes are the reservoir of many pathogenic bacteria including pneumococci, staphylococci and streptococci) (Coello et al., 1994; De Lencastre et al., 1999; Fischetti, 2003). Lysin engineering is of special promise to create enzybiotics with novel characteristics.

Chimeric lysins (also called chimeolysins) have been created by shuffling the domains, i.e., the cell wall binding domains (CBDs) and the catalytic domains (CDs) from natural lysins. Interestingly, the natural lysin Pal, identified from pneumococcal phage Dp-1, has proven to be a natural chimeolysin of intergeneric origin (Sheehan et al., 1997). Artificial lysins (also known as artilysins) have been created by fusing a natural lysin or part of its domain with another component that came from either a peptide or a protein. While natural lysins essentially lyse only Gram-positive bacteria exogenously, some artilysins could kill Gram-negative bacteria directly from without (Lukacik et al., 2012; Briers et al., 2014a). Therefore, developing engineered lysins may help to create novel enzybiotics with improved lytic activity and spectrum against both Gram-positive and negative bacterial pathogens, and provide novel clues to understand the modular evolution of lysins (Diaz et al., 1990). This review will outline the characteristics and the remarkable potency of engineered lysins in killing pathogenic bacteria both *in vitro* and *in vivo*.

THE ACTION MODEL OF LYSINS

Differing from the traditional antibiotics, the anti-infective activity of lysin comes from its direct cell lysis upon contact with the bacterial cell wall. Lysins are expressed and accumulated in the cytosol of the host cell at the end of the phage replicative cycle (Young, 1992). With the help of another protein, the holin, lysins get access to their peptidoglycan substrate and cause rapid cell lysis (Wang et al., 2000). The holin-lysin system is essential for host cell lysis, and the molecular mechanisms underlying the procedure of “lysis from within” has been well discussed previously (Young and Wang, 2006).

When applied exogenously as recombinant enzymes, lysins have been demonstrated to cause rapid lysis of Gram-positive bacteria (Loessner et al., 1995). It is this potent ability to cause “lysis from without” of pathogenic Gram-positive cells upon direct contact with peptidoglycan that has laid the foundation of exploiting lysins as enzybiotics (Abedon, 2011). However, in the case of Gram-negative bacteria, the outer membrane hinders the access of lysins to their peptidoglycan substrates in the cell wall and therefore, their antibacterial is limited.

THE MODULAR STRUCTURE OF LYSIN

Most frequently, lysins displayed a typically modular structure of at least two distinct domains (Villa and Crespo, 2010). That is an N-terminal CD and a C-terminal CBD, corresponding to their two basic functions: enzymatic hydrolysis and substrate recognition (Figure 1). In a few cases, lysins, particularly staphylococcal lysins, have been found to have more than one CDs and one CBD (Navarre et al., 1999; Rigden et al., 2003; Donovan et al., 2006b; Sass and Bierbaum, 2007; Obeso et al., 2008). Extraordinarily, a bacillus phage lysin, plyG, has been shown to have one CD and two separate binding domains, a CBD and a spore binding domain (SBD) (Yang et al., 2012). And the C1 streptococcal phage lysin, PlyC, is shown by crystallization to be a multimeric enzyme composed of eight cell wall binding subunits for each catalytic subunit (Nelson et al., 2006; McGowan et al., 2012).

Although CBD is necessary for most lysins, truncation of some lysins to remove the CBD can result in improved lytic activity without loss of specificity (Loessner et al., 1999; Horgan et al., 2009; Fenton et al., 2010a). One good example is lysin Ply187, the CD from lysin Ply187 (N-terminal 157 amino acids) has a much higher amidase activity than the whole lysin (Loessner et al., 1999).

Generally, the CD gets access to and specifically cleaves the major bonds in the peptidoglycan *via* the specific recognition of the CBD. The substrates of CBDs are postulated to be unique and conserved molecules in the cell walls that are essential for bacterial viability, usually neutral polysaccharides that are restricted to particular species or even strains. For instance, pneumococcal phage lysin targets choline, an indispensable cell wall molecule for anchoring in *S. pneumonia* (Garcia et al., 1988; Hermoso et al., 2003). The CBDs of *Listeria* phage lysins can even distinguish various serotypes of *Listeria* species in liquid or food samples (Loessner et al., 2002; Schmelcher et al., 2010; Eugster et al., 2011; Eugster and Loessner, 2012). Because of the relatively independent functions of these two domains, engineered lysins can be constructed by shuffling these domains from different origin or fusing them with other molecules. By doing so, the chimera may be empowered with new characteristics, including binding specificity, killing spectrum, solubility, stability, activity and so on.




Table 1 | The structural composition and characteristics of engineered lysins.

	N-terminal donor	C-terminal donor	Property	Antimicrobial spectrum	Ref.
CHIMEOLYSIN					
ClyS	Phage Twort lysin plyTW, endopeptidase	phiNM3 lysin	Highly soluble, superiority to mupirocin for skin decolonization	Staphylococci	Daniel et al., 2010; Pastagia et al., 2011
Lys168-87	<i>E. faecalis</i> phage F168/08 lysin, CHAP ^a	Phage 87 lysin Lys87 ^b	Highly soluble, broad antimicrobial activity	Staphylococci, <i>E. faecalis</i> , <i>E. faecium</i> , <i>S. pyogenes</i>	Fernandes et al., 2012
Lys170-87	<i>E. faecalis</i> phage F170/08 lysin, amidase	Phage 87 lysin Lys87 ^b	Highly soluble, broad antimicrobial activity	Staphylococci, <i>E. faecalis</i> , <i>E. faecium</i> , <i>S. pyogenes</i>	Fernandes et al., 2012
PRF-119	Phage K lysin plyK, CHAP	Lysostaphin, SH3b like domain	Very good activity	Staphylococci	Idelevich et al., 2011
λSA2-E-Lyso-SH3b	Phage λSA2 lysin, endopeptidase	Lysostaphin, SH3b like domain	Increased activity and extended lytic spectrum	Staphylococci, Streptococci	Becker et al., 2009; Schmelcher et al., 2012
λSA2-E-LysK-SH3b	Phage λSA2 lysin, endopeptidase	LysK, SH3b like domain	Increased activity and extended lytic spectrum	Staphylococci, Streptococci	Becker et al., 2009; Schmelcher et al., 2012
B30-182-Lyso	Phage B30 lysin, endopeptidase	Lysostaphin, SH3b like domain	Extended lytic spectrum and binding capacity	<i>S. aureus</i> , <i>S. uber</i> , <i>S. agalactiae</i> , <i>S. dysgalactiae</i>	Donovan et al., 2006a
Ply187AN-KSH3b	Phage 187 lysin Ply187, amidase	LysK, SH3b like domain	Improved lytic activity	Staphylococci	Mao et al., 2013
ClyH	Phage 187 lysin Ply187, amidase	phiNM3 lysin	Improved lytic activity and extended lytic spectrum	Staphylococci, <i>S. sobrinus</i>	Yang et al., 2014
Ply187N-V12C	Phage 187 lysin Ply187, amidase	Lysin PlyV12, SH3b like domain	Extend lytic spectrum	Staphylococci, <i>Streptococci</i> , <i>Enterococci</i>	Dong et al., 2014
ARTILYSIN					
P128	tail-associated enzyme of Phage K	Lysostaphin, SH3b like domain	High lytic activity	Staphylococci	Vipra et al., 2012
P16-17	Phage p68 lysin p16, CHAP	Minor coat protein 17 of phage p68 ^b	Highly soluble	<i>S. aureus</i>	Manoharadas et al., 2009
CLL	lysin Cpl-1, lysozyme	LytA C-terminal domain	Altered binding capacity	Streptococci	Diaz et al., 1990
CLA	LytA amidase domain	Lysin Cpl-1 binding domain	Altered binding capacity	Streptococci	Diaz et al., 1990
Art-085	SMAP-29 peptide	Lysin KZ144	Kills Gram-negative bacteria	<i>P. aeruginosa</i> , <i>P. syringae</i> , <i>P. putida</i>	Briers et al., 2014a
Pesticin-like	T4 lysozyme	Pesticin	Kills Gram-negative bacteria	<i>Yersinia</i> , <i>E. coli</i> expressing FyuA	Lukacik et al., 2012
LoGT series	Various peptides ^c	Various lysins ^d	Kills Gram-negative bacteria	<i>P. aeruginosa</i> , <i>A. baumannii</i> , <i>E. coli</i> , <i>S. Typhimurium</i>	Briers et al., 2014b

^aCHAP: cysteine and histidine-dependent aminopeptidase/hydrolase.

^bThe characters of these CBDs cannot be confirmed for their sequences are unavailable.

^cThese peptides include α4, MW1, MW2, polycationic peptide (PCNP), hydrophobic pentapeptide (HPP), Parasin1 (Pa1), and lycotoxin1 (Ly1).

^dThese lysins include OBPgp279 (YP_004958186.1), PVP-SE1gp146 (YP_004893953.1), phiKZgp144 (NP_803710.1), 201φ2-1gp229 (YP_001956952.1), CR8gp3.5, P2gp09 (NP_046765.1), and PsP3gp10 (NP_958065.1).

CHIMEOLYSIN

A chimeolysin could be designed to have an improved lytic activity, or a broader lytic spectrum, compared with its parental enzyme (Table 1). For instance, the specific lytic activity of Ply187AN-KSH3b, a chimeolysin constructed by fusing the amidase of lysin Ply187 with the LysK SH-3b CBD, was 10-fold higher than that of its parental lysin Ply187AN (Mao et al., 2013). Specifically, by adding the non-SH3b-like CBD of phiNM3 to the CD of Ply187 (giving rises to chimeolysin ClyH) yielded a 3.7–13.6 fold increase in lytic activity against *S. aureus* (Yang et al., 2014). ClyH could even lyse *S. sobrinus*, a streptococci that Ply187 could not lyse at all. Similar results are seen with a chimeolysin Ply187N-V12C, however in this case, the chimeolysin has an extended lytic activity against *S. dysgalactiae*, the main pathogen of cow mastitis (Dong et al., 2014).

In some cases, the lytic spectrum of a chimeolysin may be altered by changing its CBD. The streptococcal λ Sa2 prophage endolysin has a strong lytic activity against multiple streptococcal strains but not staphylococcal pathogens (Donovan and Foster-Frey, 2008). Replacing its Cpl-7 CBD with a staphylococcal SH3b domain from either lysostaphin or LysK resulted in a 5-fold increase in staphylolytic activity, and surprisingly, the chimera also maintained significant streptolytic activity (Becker et al., 2009). Similarly, bioengineering different CBDs of Listeria phage lysins provides extended recognition and binding properties (Schmelcher et al., 2011).

Daniel et al. constructed chimeolysins to solve the solubility problems associated with natural lysins. By fusing the CD of phage Twort lysin to the CBD of phiNM3 lysin, they created a highly soluble chimera, ClyS, which was shown to have potent anti-infective efficacy against MRSA in a murine sepsis model (Daniel et al., 2010). ClyS has also shown superior to mupirocin for skin decolonization of methicillin-resistant and -sensitive *S. aureus* strains in mice (Pastagia et al., 2011). In another work, Fernandes et al. were able to improve the solubility and antimicrobial activity of Lys87, via substituting its CD with a CD from an enterococcal lysin that is highly soluble (Fernandes et al., 2012).

There is also an example of a chimeolysin that was designed to avoid resistance to phages. The chimera PRF-119 has been proven to kill four phage-resistant *S. aureus* mutants (Idelevich et al., 2011), and at the same time, showed very good activities against *S. aureus* with MIC₉₀ of 0.391 μ g/ml for 398 MSSA and 776 MRSA clinical isolates, respectively.

ARTILYSIN

Artilysin denotes an engineered enzybiotic created by fusing a fragment of a natural lysin with peptides or other proteins (Figure 1). One outstanding application is to design artilyns against Gram-negative bacteria (Table 1). In recent research, Briers et al. (2014a) designed an artilysin with a highly efficient antibacterial activity against multidrug resistant strains and persisters of *Pseudomonas aeruginosa*, by fusing a sheep myeloid antimicrobial peptide with 29 amino acids residues (SMAP-29) to the N-terminus of the endolysin KZ144. SMAP-29 is an α -helical cathelicidin found in sheep leukocytes that can pass the outer membrane of Gram-negative bacteria via a self-promoted

uptake pathway (Skerlavaj et al., 1999). It is well known that antimicrobial peptides kill bacteria either by disrupting the cytoplasmic membrane or by crossing the membrane and acting on intracellular targets, however, such peptides are cytotoxic to mammalian cells (Maher and McClean, 2006; Dawson and Liu, 2009). Meanwhile, the natural form of lysin KZ144 could not kill *P. aeruginosa* cells directly, but was effective against membrane-permeated cells, which are obtained by treatment with chloroform (Briers et al., 2007), or under high hydrostatic pressure (Briers et al., 2008). Surprisingly, the artilysin overcomes the disadvantages of its both donors. The artilysin not only kills the *P. aeruginosa* cells directly, but also shows no cytotoxicity, indicating that the application of bacteriophage lysins as enzybiotics must not be limited only to Gram-positive pathogens.

Very recently, Briers and coworkers described a series of artilyns that are highly active against Gram-negative pathogens. For instance, artilysin LoGT-23, can cause a reduction of 5.5 log, 5.2 log, 2.4 log and 1.5 log for *P. aeruginosa*, *Acinetobacter baumannii*, *E. coli* and *Salmonella Typhimurium* within 30 min in the presence of 0.5 mM EDTA, respectively. The *in vivo* efficacy of some artilyns have also been tested in a *Caenorhabditis elegans* bacterial infection model, indicating that artilyns may have broad anti-infective applications.

In another example, Lukacik et al. constructed a pesticin-like hybrid toxin that kills specific *Yersinia* and pathogenic *E. coli* strains, by attaching an FyuA targeting domain to the N-terminus of T4 lysozyme (Lukacik et al., 2012). The hybrid could pass the out membrane in order to reach the peptidoglycan layer through the interaction with the outer membrane transporter FyuA. Moreover, the hybrid toxin can evade the pesticin immunity protein (Pim) indicating that it may be a potential candidate for *in vivo* therapy over pesticin. Because FyuA is more common in pathogenic bacteria, the hybrid toxin harbors a great potential to kill pathogenic bacteria specifically.

CONCLUDING REMARKS

Bacteriophage lysins demonstrate several highly desirable properties compared with antibiotics, which include novel antimicrobial mechanisms, high specificity and activity against multidrug resistant pathogens, as well as a low possibility of developing resistance. The huge number of phages existing on earth supports great resources for lysin discovery. Meanwhile, the modular structure of lysins provides a great chance to create engineered lysins with desired properties, which may include extended killing spectra, enhanced killing activity, and improved solubility. Through rational design of natural lysins, artilyns can even kill Gram-negative bacteria that are resistant to natural lysins. Taken all these together, engineered lysins represent a new class of enzybiotics that are powerful and readily available to fight the emerging antimicrobial resistance.

ACKNOWLEDGMENTS

This work was supported by the Basic Research Program of the Ministry of Science and Technology of China (2012CB721102), the Chinese Academy of Sciences (KJZD-EW-L02), the National Natural Science Foundation of China (31400126), and the Key Laboratory on Emerging Infectious Diseases and Biosafety, CAS.

REFERENCES

- Abedon, S. T. (2011). Lysis from without. *Bacteriophage* 1, 46–49. doi: 10.4161/bact.1.1.13980
- Becker, S. C., Foster-Frey, J., Stodola, A. J., Anacker, D., and Donovan, D. M. (2009). Differentially conserved staphylococcal SH3b_5 cell wall binding domains confer increased staphylococcal and streptococcal activity to a streptococcal prophage endolysin domain. *Gene* 443, 32–41. doi: 10.1016/j.gene.2009.04.023
- Briers, Y., Cornelissen, A., Aertsen, A., Hertveldt, K., Michiels, C. W., Volckaert, G., et al. (2008). Muralytic activity and modular structure of the endolysins of *Pseudomonas aeruginosa* bacteriophages phiKZ and EL. *Mol. Microbiol.* 65, 1334–1344. doi: 10.1111/j.1365-2958.2007.05870.x
- Briers, Y., Walmagh, M., Grymonprez, B., Biebl, M., Pirnay, J. P., Defraigne, V., et al. (2014a). Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persists of *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* 58, 3774–3784. doi: 10.1128/AAC.02668-14
- Briers, Y., Walmagh, M., Van Puyenbroeck, V., Cornelissen, A., Cenens, W., Aertsen, A., et al. (2014b). Engineered endolysin-based “artilysins” to combat multidrug-resistant gram-negative pathogens. *MBio* 5, e01379–14. doi: 10.1128/mBio.01379-14
- Callewaert, L., Walmagh, M., Michiels, C. W., and Lavigne, R. (2011). Food applications of bacterial cell wall hydrolases. *Curr. Opin. Biotechnol.* 22, 164–171. doi: 10.1016/j.copbio.2010.10.012
- Cheng, Q., Nelson, D., Zhu, S., and Fischetti, V. A. (2005). Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. *Antimicrob. Agents Chemother.* 49, 111–117. doi: 10.1128/AAC.49.1.111-117.2005
- Coello, R., Jimenez, J., Garcia, M., Arroyo, P., Minguéz, D., Fernandez, C., et al. (1994). Prospective study of infection, colonization and carriage of methicillin-resistant *Staphylococcus aureus* in an outbreak affecting 990 patients. *Eur. J. Clin. Microbiol. Infect. Dis.* 13, 74–81. doi: 10.1007/BF02026130
- Daniel, A., Euler, C., Collin, M., Chahales, P., Gorelick, K. J., and Fischetti, V. A. (2010). Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 54, 1603–1612. doi: 10.1128/AAC.01625-09
- Dawson, R. M., and Liu, C. Q. (2009). Cathelicidin peptide SMAP–29: comprehensive review of its properties and potential as a novel class of antibiotics. *Drug Develop. Res.* 70, 481–498. doi: 10.1002/ddr.20329
- De Lencastre, H., Kristinsson, K. G., Brito-Avo, A., Sanches, I. S., Sa-Leao, R., Saldanha, J., et al. (1999). Carriage of respiratory tract pathogens and molecular epidemiology of *Streptococcus pneumoniae* colonization in healthy children attending day care centers in Lisbon, Portugal. *Microb. Drug Resist.* 5, 19–29. doi: 10.1089/mdr.1999.5.19
- Diaz, E., Lopez, R., and Garcia, J. L. (1990). Chimeric phage-bacterial enzymes: a clue to the modular evolution of genes. *Proc. Natl. Acad. Sci. U.S.A.* 87, 8125–8129. doi: 10.1073/pnas.87.20.8125
- Dong, Q., Wang, J., Yang, H., Yu, J., Zhang, Y., Huang, Y., et al. (2014). Construction of a chimeric lysin Ply187N-V12C with extended lytic activity against staphylococci and streptococci. *Microb. Biotechnol.* doi: 10.1111/1751-7915.12166. [Epub ahead of print].
- Donovan, D. M., Dong, S., Garrett, W., Rousseau, G. M., Moineau, S., and Pritchard, D. G. (2006a). Peptidoglycan hydrolase fusions maintain their parental specificities. *Appl. Environ. Microbiol.* 72, 2988–2996. doi: 10.1128/AEM.72.4.2988-2996.2006
- Donovan, D. M., and Foster-Frey, J. (2008). LambdaSa2 prophage endolysin requires Cpl-7-binding domains and amidase-5 domain for antimicrobial lysis of streptococci. *FEMS Microbiol. Lett.* 287, 22–33. doi: 10.1111/j.1574-6968.2008.01287.x
- Donovan, D. M., Lardeo, M., and Foster-Frey, J. (2006b). Lysis of staphylococcal mastitis pathogens by bacteriophage phi11 endolysin. *FEMS Microbiol. Lett.* 265, 133–139. doi: 10.1111/j.1574-6968.2006.00483.x
- Entenza, J. M., Loeffler, J. M., Grandgirard, D., Fischetti, V. A., and Moreillon, P. (2005). Therapeutic effects of bacteriophage Cpl-1 lysin against *Streptococcus pneumoniae* endocarditis in rats. *Antimicrob. Agents Chemother.* 49, 4789–4792. doi: 10.1128/AAC.49.11.4789-4792.2005
- Eugster, M. R., Haug, M. C., Huwiler, S. G., and Loessner, M. J. (2011). The cell wall binding domain of *Listeria* bacteriophage endolysin PlyP35 recognizes terminal GlcNAc residues in cell wall teichoic acid. *Mol. Microbiol.* 81, 1419–1432. doi: 10.1111/j.1365-2958.2011.07774.x
- Eugster, M. R., and Loessner, M. J. (2012). Wall teichoic acids restrict access of bacteriophage endolysin Ply118, Ply511, and PlyP40 cell wall binding domains to the *Listeria monocytogenes* peptidoglycan. *J. Bacteriol.* 194, 6498–6506. doi: 10.1128/JB.00808-12
- Fenton, M., Casey, P. G., Hill, C., Gahan, C. G., Ross, R. P., McAuliffe, O., et al. (2010a). The truncated phage lysin CHAP(k) eliminates *Staphylococcus aureus* in the nares of mice. *Bioeng. Bugs* 1, 404–407. doi: 10.4161/bbug.1.6.13422
- Fenton, M., Ross, P., McAuliffe, O., O'Mahony, J., and Coffey, A. (2010b). Recombinant bacteriophage lysins as antibacterials. *Bioeng. Bugs* 1, 9–16. doi: 10.4161/bbug.1.1.9818
- Fernandes, S., Proenca, D., Cantante, C., Silva, F. A., Leandro, C., Lourenco, S., et al. (2012). Novel chimerical endolysins with broad antimicrobial activity against methicillin-resistant *Staphylococcus aureus*. *Microb. Drug Resist.* 18, 333–343. doi: 10.1089/mdr.2012.0025
- Fischetti, V. A. (2005). Novel method to control pathogenic bacteria on human mucous membranes. *Ann. N.Y. Acad. Sci.* 987, 207–214. doi: 10.1111/j.1749-6632.2003.tb06050.x
- Fischetti, V. A. (2005). Bacteriophage lytic enzymes: novel anti-infectives. *Trends Microbiol.* 13, 491–496. doi: 10.1016/j.tim.2005.08.007
- Fischetti, V. A. (2006). Using phage lytic enzymes to control pathogenic bacteria. *BMC Oral Health* 6(Suppl. 1):S16. doi: 10.1186/1472-6831-6-S1-S16
- Fischetti, V. A. (2008). Bacteriophage lysins as effective antibacterials. *Curr. Opin. Microbiol.* 11, 393–400. doi: 10.1016/j.mib.2008.09.012
- Fischetti, V. A. (2010). Bacteriophage endolysins: a novel anti-infective to control gram-positive pathogens. *Int. J. Med. Microbiol.* 300, 357–362. doi: 10.1016/j.ijmm.2010.04.002
- Fischetti, V. A., Nelson, D., and Schuch, R. (2006). Reinventing phage therapy: are the parts greater than the sum? *Nat. Biotechnol.* 24, 1508–1511. doi: 10.1038/nbt1206-1508
- Garcia, E., Garcia, J. L., Garcia, P., Arraras, A., Sanchez-Puelles, J. M., and Lopez, R. (1988). Molecular evolution of lytic enzymes of *Streptococcus pneumoniae* and its bacteriophages. *Proc. Natl. Acad. Sci. U.S.A.* 85, 914–918. doi: 10.1073/pnas.85.3.914
- George, S. E., Chikkamadaiah, R., Durgaiya, M., Joshi, A. A., Thankappan, U. P., Madhusudhana, S. N., et al. (2012). Biochemical characterization and evaluation of cytotoxicity of antistaphylococcal chimeric protein P128. *BMC Res. Notes* 5:280. doi: 10.1186/1756-0500-5-280
- Gilmer, D. B., Schmitz, J. E., Euler, C. W., and Fischetti, V. A. (2013). Novel bacteriophage lysin with broad lytic activity protects against mixed infection by *Streptococcus pyogenes* and methicillin-resistant *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 57, 2743–2750. doi: 10.1128/AAC.02526-12
- Grandgirard, D., Loeffler, J. M., Fischetti, V. A., and Leib, S. L. (2008). Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. *J. Infect. Dis.* 197, 1519–1522. doi: 10.1086/587942
- Hermoso, J. A., Monterroso, B., Albert, A., Galan, B., Ahrazem, O., Garcia, P., et al. (2003). Structural basis for selective recognition of pneumococcal cell wall by modular endolysin from phage Cp-1. *Structure* 11, 1239–1249. doi: 10.1016/j.str.2003.09.005
- Horgan, M., O'Flynn, G., Garry, J., Cooney, J., Coffey, A., Fitzgerald, G. F., et al. (2009). Phage lysin LysK can be truncated to its CHAP domain and retain lytic activity against live antibiotic-resistant staphylococci. *Appl. Environ. Microbiol.* 75, 872–874. doi: 10.1128/AEM.01831-08
- Idelevich, E. A., Von Eiff, C., Friedrich, A. W., Iannelli, D., Xia, G., Peters, G., et al. (2011). *In vitro* activity against *Staphylococcus aureus* of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin. *Antimicrob. Agents Chemother.* 55, 4416–4419. doi: 10.1128/AAC.00217-11
- Junjappa, R. P., Desai, S. N., Roy, P., Narasimhaswamy, N., Raj, J. R., Durgaiya, M., et al. (2013). Efficacy of anti-staphylococcal protein P128 for the treatment of canine pyoderma: potential applications. *Vet. Res. Commun.* 37, 217–228. doi: 10.1007/s11259-013-9565-y
- Kiser, K. B., Cantey-Kiser, J. M., and Lee, J. C. (1999). Development and characterization of a *Staphylococcus aureus* nasal colonization model in mice. *Infect. Immun.* 67, 5001–5006.

- Knoll, B. M., and Mylonakis, E. (2014). Antibacterial bioagents based on principles of bacteriophage biology: an overview. *Clin. Infect. Dis.* 58, 528–534. doi: 10.1093/cid/cit771
- Loeffler, J. M., Nelson, D., and Fischetti, V. A. (2001). Rapid killing of *Streptococcus pneumoniae* with a bacteriophage cell wall hydrolase. *Science* 294, 2170–2172. doi: 10.1126/science.1066869
- Loessner, M. J. (2005). Bacteriophage endolysins—current state of research and applications. *Curr. Opin. Microbiol.* 8, 480–487. doi: 10.1016/j.mib.2005.06.002
- Loessner, M. J., Gaeng, S., and Scherer, S. (1999). Evidence for a holin-like protein gene fully embedded out of frame in the endolysin gene of *Staphylococcus aureus* bacteriophage 187. *J. Bacteriol.* 181, 4452–4460.
- Loessner, M. J., Kramer, K., Ebel, F., and Scherer, S. (2002). C-terminal domains of *Listeria monocytogenes* bacteriophage murein hydrolases determine specific recognition and high-affinity binding to bacterial cell wall carbohydrates. *Mol. Microbiol.* 44, 335–349. doi: 10.1046/j.1365-2958.2002.02889.x
- Loessner, M. J., Schneider, A., and Scherer, S. (1995). A new procedure for efficient recovery of DNA, RNA, and proteins from *Listeria* cells by rapid lysis with a recombinant bacteriophage endolysin. *Appl. Environ. Microbiol.* 61, 1150–1152.
- Lukacik, P., Barnard, T. J., Keller, P. W., Chaturvedi, K. S., Seddiki, N., Fairman, J. W., et al. (2012). Structural engineering of a phage lysin that targets gram-negative pathogens. *Proc. Natl. Acad. Sci. U.S.A.* 109, 9857–9862. doi: 10.1073/pnas.1203472109
- Maher, S., and McClean, S. (2006). Investigation of the cytotoxicity of eukaryotic and prokaryotic antimicrobial peptides in intestinal epithelial cells *in vitro*. *Biochem. Pharmacol.* 71, 1289–1298. doi: 10.1016/j.bcp.2006.01.012
- Manoharadas, S., Witte, A., and Blasi, U. (2009). Antimicrobial activity of a chimeric enzymatic towards *Staphylococcus aureus*. *J. Biotechnol.* 139, 118–123. doi: 10.1016/j.jbiotec.2008.09.003
- Mao, J., Schmelcher, M., Harty, W. J., Foster-Frey, J., and Donovan, D. M. (2013). Chimeric Ply187 endolysin kills *Staphylococcus aureus* more effectively than the parental enzyme. *FEMS Microbiol. Lett.* 1, 30–36. doi: 10.1111/1574-6968.12104
- McGowan, S., Buckle, A. M., Mitchell, M. S., Hoopes, J. T., Gallagher, D. T., Heselpoth, R. D., et al. (2012). X-ray crystal structure of the streptococcal specific phage lysin PlyC. *Proc. Natl. Acad. Sci. U.S.A.* 109, 12752–12757. doi: 10.1073/pnas.1208424109
- Navarre, W. W., Ton-That, H., Faull, K. F., and Schneewind, O. (1999). Multiple enzymatic activities of the murein hydrolase from staphylococcal phage phi11. Identification of a D-alanyl-glycine endopeptidase activity. *J. Biol. Chem.* 274, 15847–15856. doi: 10.1074/jbc.274.22.15847
- Nelson, D., Schuch, R., Chahales, P., Zhu, S., and Fischetti, V. A. (2006). PlyC: a multimeric bacteriophage lysin. *Proc. Natl. Acad. Sci. U.S.A.* 103, 10765–10770. doi: 10.1073/pnas.0604521103
- Obeso, J. M., Martinez, B., Rodriguez, A., and Garcia, P. (2008). Lytic activity of the recombinant staphylococcal bacteriophage PhiH5 endolysin active against *Staphylococcus aureus* in milk. *Int. J. Food Microbiol.* 128, 212–218. doi: 10.1016/j.ijfoodmicro.2008.08.010
- Oliveira, H., Azeredo, J., Lavigne, R., and Kluskens, L. D. (2012). Bacteriophage endolysins as a response to emerging foodborne pathogens. *Trends Food Sci. Technol.* 28, 103–115. doi: 10.1016/j.tifs.2012.06.016
- Pastagia, M., Euler, C., Chahales, P., Fuentes-Duculan, J., Krueger, J. G., and Fischetti, V. A. (2011). A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive *Staphylococcus aureus* strains. *Antimicrob. Agents Chemother.* 55, 738–744. doi: 10.1128/AAC.00890-10
- Pastagia, M., Schuch, R., Fischetti, V. A., and Huang, D. B. (2013). Lysins: the arrival of pathogen-directed anti-infectives. *J. Med. Microbiol.* 62, 1506–1516. doi: 10.1099/jmm.0.061028-0
- Rashel, M., Uchiyama, J., Ujihara, T., Uehara, Y., Kuramoto, S., Sugihara, S., et al. (2007). Efficient elimination of multidrug-resistant *Staphylococcus aureus* by cloned lysin derived from bacteriophage phi MR11. *J. Infect. Dis.* 196, 1237–1247. doi: 10.1086/521305
- Rigden, D. J., Jedrzejas, M. J., and Galperin, M. Y. (2003). Amidase domains from bacterial and phage autolysins define a family of gamma-D,L-glutamate-specific amidohydrolases. *Trends Biochem. Sci.* 28, 230–234. doi: 10.1016/S0968-0004(03)00062-8
- Sass, P., and Bierbaum, G. (2007). Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of *Staphylococcus aureus*. *Appl. Environ. Microbiol.* 73, 347–352. doi: 10.1128/AEM.01616-06
- Schmelcher, M., Powell, A. M., Becker, S. C., Camp, M. J., and Donovan, D. M. (2012). Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing *Staphylococcus aureus* in murine mammary glands. *Appl. Environ. Microbiol.* 78, 2297–2305. doi: 10.1128/AEM.07050-11
- Schmelcher, M., Shabarova, T., Eugster, M. R., Eichenseher, F., Tchang, V. S., Banz, M., et al. (2010). Rapid multiplex detection and differentiation of *Listeria* cells by use of fluorescent phage endolysin cell wall binding domains. *Appl. Environ. Microbiol.* 76, 5745–5756. doi: 10.1128/AEM.00801-10
- Schmelcher, M., Tchang, V. S., and Loessner, M. J. (2011). Domain shuffling and module engineering of *Listeria* phage endolysins for enhanced lytic activity and binding affinity. *Microb. Biotechnol.* 4, 651–662. doi: 10.1111/j.1751-7915.2011.00263.x
- Schuch, R., Lee, H. M., Schneider, B. C., Sauve, K. L., Law, C., Khan, B. K., et al. (2014). Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant *Staphylococcus aureus*-induced murine bacteremia. *J. Infect. Dis.* 209, 1469–1478. doi: 10.1093/infdis/jit637
- Schuch, R., Nelson, D., and Fischetti, V. A. (2002). A bacteriolytic agent that detects and kills *Bacillus anthracis*. *Nature* 418, 884–889. doi: 10.1038/nature01026
- Sheehan, M. M., Garcia, J. L., Lopez, R., and Garcia, P. (1997). The lytic enzyme of the pneumococcal phage Dp-1: a chimeric lysin of intergeneric origin. *Mol. Microbiol.* 25, 717–725. doi: 10.1046/j.1365-2958.1997.5101880.x
- Singh, P. K., Donovan, D. M., and Kumar, A. (2014). Intravitreal injection of the chimeric phage endolysin Ply187 protects mice from *Staphylococcus aureus* endophthalmitis. *Antimicrob. Agents Chemother.* 58, 4621–4629. doi: 10.1128/AAC.00126-14
- Skerlavaj, B., Benincasa, M., Risso, A., Zanetti, M., and Gennaro, R. (1999). SMAP-29: a potent antibacterial and antifungal peptide from sheep leukocytes. *FEBS Lett.* 463, 58–62. doi: 10.1016/S0014-5793(99)01600-2
- Villa, T. G., and Crespo, P. V. (2010). *Enzybiotics: Antibiotic Enzymes as Drugs and Therapeutics*. Hoboken, NJ: John Wiley & Sons.
- Vipra, A. A., Desai, S. N., Roy, P., Patil, R., Raj, J. M., Narasimhaswamy, N., et al. (2012). Antistaphylococcal activity of bacteriophage derived chimeric protein P128. *BMC Microbiol.* 12:41. doi: 10.1186/1471-2180-12-41
- Wang, I. N., Smith, D. L., and Young, R. (2000). Holins: the protein clocks of bacteriophage infections. *Annu. Rev. Microbiol.* 54, 799–825. doi: 10.1146/annurev.micro.54.1.799
- Witzenrath, M., Schmeck, B., Doehn, J. M., Tschernig, T., Zahlten, J., Loeffler, J. M., et al. (2009). Systemic use of the endolysin Cpl-1 rescues mice with fatal pneumococcal pneumonia. *Crit. Care Med.* 37, 642–649. doi: 10.1097/CCM.0b013e31819586a6
- Yang, H., Wang, D. B., Dong, Q., Zhang, Z., Cui, Z., Deng, J., et al. (2012). Existence of separate domains in lysin PlyG for recognizing *Bacillus anthracis* spores and vegetative cells. *Antimicrob. Agents Chemother.* 56, 5031–5039. doi: 10.1128/AAC.00891-12
- Yang, H., Zhang, Y., Yu, J., Huang, Y., Zhang, X. E., and Wei, H. (2014). Novel chimeric lysin with high-level antimicrobial activity against methicillin-resistant *Staphylococcus aureus* *in vitro* and *in vivo*. *Antimicrob. Agents Chemother.* 58, 536–542. doi: 10.1128/AAC.01793-13
- Young, R. (1992). Bacteriophage lysis: mechanism and regulation. *Microbiol. Rev.* 56, 430–481.
- Young, R., and Wang, I. (2006). “Phage lysis,” in *The Bacteriophages*, ed R. Calendar (Oxford: Oxford University Press), 104–126.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 23 August 2014; accepted: 29 September 2014; published online: 16 October 2014.

Citation: Yang H, Yu J and Wei H (2014) Engineered bacteriophage lysins as novel anti-infectives. *Front. Microbiol.* 5:542. doi: 10.3389/fmicb.2014.00542

This article was submitted to *Antimicrobials, Resistance and Chemotherapy*, a section of the journal *Frontiers in Microbiology*.

Copyright © 2014 Yang, Yu and Wei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.